penpulimab + paclitaxel + cisplatin

Penpulimab + paclitaxel + cisplatin is a **combination regimen of three drugs** used for cancer treatment: - **Penpulimab** is a humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting **programmed death protein 1 (PD-1)**, blocking its interaction with PD-L1 and PD-L2, thereby releasing PD-1 pathway-mediated inhibition of anti-tumor immune response[1][5]. Developed as a next-generation PD-1 inhibitor, penpulimab features modifications to its Fc region to minimize immune-related adverse events and has been studied in multiple solid tumors, including upper gastrointestinal cancers and relapsed classical Hodgkin lymphoma[1][3][5]. - **Paclitaxel** is a microtubule-stabilizing **chemotherapy agent** that promotes microtubule assembly and inhibits their disassembly, leading to cell cycle arrest and apoptosis. - **Cisplatin** is a **platinum-based chemotherapy drug** that forms DNA crosslinks, thereby disrupting DNA synthesis and resulting in apoptosis of cancer cells[2][4][6]. This combination is under investigation for use in a range of malignancies where immune checkpoint inhibition and platinum/taxane chemotherapy may have synergistic or additive effects.